|Bid||0.00 x 900|
|Ask||0.00 x 3100|
|Day's Range||12.61 - 13.18|
|52 Week Range||10.21 - 23.62|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
If you're interested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), then you might want to consider its beta (a...
Investors need to pay close attention to Intra-Cellular (ITCI) stock based on the movements in the options market lately.
The market suffered a sharp selloff on Monday as China announced new tariffs effective June 1 on $60 billion of imports from the U.S. That action was response to the Trump administration's decision the previous week to raise tariffs from 10% to 25% on $200 billion of imports from China after the Chinese delegation reneged on several key provisions of a new trade deal. The administration did mend fences on the trade front elsewhere to bring its full attention to bear on China. In addition, aluminum and steel tariffs on Canada were dropped.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
The New York-based company said it had a loss of 63 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you love investing in stocks you're bound to buy some losers. Long term Intra-Cellular Therapies, Inc. (NASDAQ:ITCI...
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
Sharon Mates became the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
If you own shares in Intra-Cellular Therapies Inc (NASDAQ:ITCI) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
On a per-share basis, the New York-based company said it had a loss of 76 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Intra-Cellular (ITCI) needs investors to pay close attention to the stock based on moves in the options market lately.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Intra-Cellular Therapies Inc (NASDAQ:ITCI), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...
Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018